Description and Brand Names
Drug information provided by: Merative, Micromedex®
US Brand Name
- Herceptin Hylecta
Descriptions
Trastuzumab and hyaluronidase-oysk combination injection is used together with other cancer medicines (eg, doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, docetaxel and carboplatin, or after anthracycline medicine) to treat HER2-overexpressing node-positive or node-negative (ER/PR negative or with one high risk feature) breast cancer.
Trastuzumab and hyaluronidase-oysk combination injection is also used together with paclitaxel for the first-line treatment of HER2-overexpressing metastatic (cancer that has spread) breast cancer. It is also used to treat HER2-overexpressing metastatic breast cancer in patients who have received one or more chemotherapy treatments.
Trastuzumab and hyaluronidase-oysk combination prevents the growth of some tumors that produce extra amounts of a certain substance known as the HER2 protein. It should only be used in patients whose tumors have been shown to produce extra amounts of this protein (HER2 overexpression).
This medicine is to be given only by or under the direct supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: Feb. 01, 2024
Copyright: © Merative US L.P. 1973, 2024. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.